Page 29 - Sofinnova Partners News Today

Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholdersThe new funds will be used to advance iOmx' lead programs IMT-07 and

/PRNewswire/ -- EnginZyme, a leading developer of cell-free biomanufacturing processes, has today announced the breakthrough result from piloting a process to...

Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

/PRNewswire/ -- Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases such as the intracellular...

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive team will

Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone

Share this article Share this article GAITHERSBURG, Md., July 12, 2021 /PRNewswire/ -- MaxCyte, Inc., (LSE: MXCT) (LSE: MXCN), a leading provider of platform technologies for cell engineering (" MaxCyte" or the " Company"), today announced the public filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") for a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "offering"). The registration stateme...

Published: Jul 09, 2021 By Brandon May Muna Therapeutics, a private Denmark- and Belgium-based biopharmaceutical company founded in 2020, officially closed a $73 million Series A financing round. The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases. The Series A financing was led by Novo Holdings in conjunction with Sofinnova Partners, DROIA Ventures and LSP Dementia Fund. Additional investors who join...

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases - Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB - Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation - Innovative drug discovery platform leveraging insights from novel targets and pa...

Novo Holdings Launches Muna Therapeutics with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases - Novo Holdings created and built Muna Therapeutics with pioneers in the field of neurodegeneration - Led by an experienced management team of Entrepreneurs-in-Residence from Novo Seeds - Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventu...